Echo IQ's Strategic Integration with Beth Israel Deaconess Medical Center

Integration with Beth Israel

Echo IQ Limited has taken a significant step forward by integrating its EchoSolv-AS technology with Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. BIDMC is a renowned academic medical center affiliated with Harvard Medical School, known for its advanced medical research and patient care.

The integration follows a successful trial conducted by BIDMC researchers, which validated EchoSolv-AS's key performance metrics. The trial involved analyzing echocardiographic reports from over 31,000 patients, demonstrating the technology's high accuracy in identifying severe Aortic Stenosis (AS).

Trial Results and Impact

During the trial, EchoSolv-AS identified 98% of patients who met clinical guidelines for severe AS. Additionally, it flagged over 1,000 patients who likely had severe AS but did not meet the guidelines. These non-guideline patients had a similar risk of death as those with diagnosed severe AS, yet only a small percentage received life-extending treatment.

The findings, published in JACC Advances, highlight the potential of EchoSolv-AS to improve patient outcomes by identifying at-risk individuals who might otherwise be overlooked.

Future Prospects and Expansion

Echo IQ is providing EchoSolv-AS to BIDMC on a no-cost basis while it seeks reimbursement codes under insurance, expected in the coming quarters. This integration is anticipated to provide significant exposure for EchoSolv-AS and validate its application in real-world settings.

Echo IQ is also in advanced discussions with other US hospital groups and has already integrated EchoSolv-AS with four additional hospitals across New York, Alabama, Dallas, and Oklahoma. This expansion is part of a broader rollout strategy across the USA.